Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28288921 | 0.87 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL6978725 | 0.84 | GFER (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL9228782 | 0.83 | HRH1 (0.45) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL14842113 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL27828941 | 0.83 | DRD2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL16422478 | 0.83 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL1551829 | 0.83 | DRD2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL578547 | 0.83 | HTR2A (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL21815350 | 0.83 | HTR2A (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL27881798 | 0.83 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | disclosed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| EP-2824108-B1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| EP-2275107-B1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| CN-105640874-A | Dihydropteridinone infusion solution having a long shelf life | 贝林格尔·英格海姆国际有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| CN-1161336-C | Quinoline carboxamides as antiviral agents | �������Ŷ���Լ��������˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1333753-A | Quinoline carboxamides as antiviral agents | UPJOHN CO (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SLC6A2 3352/4885SLC6A4 3623/4885SLC6A3 4082/4885 |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | SLC6A2 3262/4885SLC6A4 3868/4885SLC6A3 3834/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | SLC6A2 4231/4885SLC6A4 3398/4885SLC6A3 3423/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | SLC6A2 3989/4885SLC6A4 3126/4885SLC6A3 2538/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SLC6A2 3352/4885SLC6A4 3623/4885SLC6A3 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.